Edition:
India

KemPharm Inc (KMPH.OQ)

KMPH.OQ on NASDAQ Stock Exchange Global Market

6.05USD
20 Apr 2018
Change (% chg)

$-0.05 (-0.82%)
Prev Close
$6.10
Open
$6.05
Day's High
$6.05
Day's Low
$5.95
Volume
10,785
Avg. Vol
26,771
52-wk High
$8.35
52-wk Low
$2.45

Select another date:

Tue, Mar 20 2018

BRIEF-Kempharm Announces Positive Topline Results From KP415 Pharmacokinetic Study In Children And Adolescents With ADHD

* KEMPHARM ANNOUNCES POSITIVE TOPLINE RESULTS FROM KP415 PHARMACOKINETIC STUDY IN CHILDREN AND ADOLESCENTS WITH ADHD

KemPharm's opioid painkiller gets FDA approval, shares soar

KemPharm Inc said on Friday the U.S. Food and Drug Administration approved its opioid painkiller Apadaz for the short-term management of acute pain, sending the shares of the drugmaker up as much as 36 percent in late afternoon trading.

UPDATE 1-KemPharm's opioid painkiller gets FDA approval, shares soar

Feb 23 KemPharm Inc said on Friday the U.S. Food and Drug Administration approved its opioid painkiller Apadaz for the short-term management of acute pain, sending the shares of the drugmaker up as much as 36 percent in late afternoon trading.

BRIEF-Kempharm Announces FDA Approval Of Apadaz

* KEMPHARM SAYS U.S. FDA APPROVED NDA FOR APADAZ FOR SHORT-TERM MANAGEMENT OF ACUTE PAIN SEVERE ENOUGH TO REQUIRE OPIOID ANALGESIC

FDA approves KemPharm's opioid painkiller

Feb 23 KemPharm Inc said on Friday the U.S. Food and Drug Administration approved its opioid painkiller Apadaz for the short-term management of acute pain. The company resubmitted the drug's marketing application for review in September last year after appealing against the drug regulator's decision to reject it in 2016.

BRIEF-KemPharm posts Q3 loss per share $0.68

* KemPharm reports third quarter 2017 results and provides corporate update

BRIEF-KemPharm receives USAN approval for “asalhydromorphone” as nonproprietary name for novel prodrug candidate, KP511

* KemPharm Inc receives USAN approval for “asalhydromorphone” as nonproprietary name for novel prodrug candidate, KP511 Source text for Eikon: Further company coverage:

BRIEF-KemPharm says KP484 allowed to proceed to clinical studies​

* kempharm’s kp484 for the treatment of adhd, an investigational prodrug of methylphenidate, allowed to proceed to clinical studies

Select another date: